Rob Lauzen is the Chief Financial Officer at Prilenia. In this position, Rob oversees all aspects of the Company’s capital strategy as well as finance and investor relations organizations.

Rob brings nearly a decade of diverse strategic and financial experience within the life science industry.  Prior to joining Prilenia, Rob served as Vice President, Investor Relations and Head of Financial Planning & Analysis at Dyne Therapeutics where his responsibilities spanned capital strategy, finance, investor relations, and business development.  Earlier in his career, Rob served as a Vice President in the healthcare investment banking group at Morgan Stanley, where he advised on a broad range of strategic and financing needs, executing over $185 billion of M&A and over $10 billion of equity transactions.

Rob graduated with a BA in Engineering Sciences from Dartmouth College.

• 

  CFO: Chief Financial Officer in Prilenia

  Pursuing Hope. Leading With Science.